Cargando…
Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3
Squamous cell lung cancer maintains its growth through elevated glucose consumption, but selective glucose consumption inhibitors are lacking. Here, we discovered using a high-throughput screen new compounds that block glucose consumption in three squamous cell lung cancer cell lines and identified...
Autores principales: | Ghezzi, Chiara, Chen, Bao Ying, Damoiseaux, Robert, Clark, Peter M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876922/ https://www.ncbi.nlm.nih.gov/pubmed/36697489 http://dx.doi.org/10.1038/s41598-023-28576-2 |
Ejemplares similares
-
A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells
por: Ghezzi, Chiara, et al.
Publicado: (2019) -
The odyssey of pacritinib in myelofibrosis
por: Venugopal, Sangeetha, et al.
Publicado: (2022) -
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
por: Hart, S, et al.
Publicado: (2011) -
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
por: Torres, Sandra, et al.
Publicado: (2023) -
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
por: Verstovsek, Srdan, et al.
Publicado: (2016)